Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Robert Pietrusko, Amy Schulman, Frank Slack

Premium

Voyager Therapeutics has appointed Robert Pietrusko as its senior vice president of regulatory affairs.

Pietrusko most recently served as vice president of global regulatory affairs and quality at ViroPharma prior to its acquisition by Shire. Before that, he was senior vice president of worldwide regulatory affairs at Millennium Pharmaceuticals.


Alnylam Pharmaceuticals has elected Amy Schulman to its board of directors.

Schulman is the former executive vice president and general counsel of Pfizer, where she also was the business unit lead for its consumer healthcare business. She currently is a senior lecturer at Harvard Business School.


Frank Slack has been appointed as the director of the Beth Israel Deaconess Medical Center's Institute for RNA Medicine, which was launched this month to foster research into the use of RNA to treat cancer and other diseases.

Slack was previously at Yale University, where he conducted key microRNA research.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.